MTOR and leukemia: DFX also exerts its anti-leukemia activity by inhibiting extracellular signal-regulated kinase (ERK) phosphorylation, repressing the mammalian target of rapamycin (mTOR) and NF-κB signaling pathway [81, 100, 101].